These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20499046)

  • 1. Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage.
    Rennings AJ; Smits P; Stewart MW; Tack CJ
    Diabetologia; 2010 Sep; 53(9):1856-66. PubMed ID: 20499046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects.
    Rennings AJ; Smits P; Stewart MW; Tack CJ
    Diabetes Care; 2006 Mar; 29(3):581-7. PubMed ID: 16505510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone-induced anasarca without heart failure: capillary leakage?
    Dagdelen S; Kurt M; Aydin K; Bayraktar M
    Hormones (Athens); 2008; 7(2):180-3. PubMed ID: 18477557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.
    Punthakee Z; Bosch J; Dagenais G; Diaz R; Holman R; Probstfield J; Ramachandran A; Riddle M; Rydén LE; Zinman B; Afzal R; Yusuf S; Gerstein H;
    Diabetologia; 2012 Jan; 55(1):36-45. PubMed ID: 22038523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.
    Zinman B; Harris SB; Neuman J; Gerstein HC; Retnakaran RR; Raboud J; Qi Y; Hanley AJ
    Lancet; 2010 Jul; 376(9735):103-11. PubMed ID: 20605202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
    Lebovitz HE; Kreider M; Freed MI
    Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus.
    Tatti P; Arrigoni F; Longobardi A; Costanza F; Di Blasi P; Merante D
    Clin Drug Investig; 2008; 28(5):327-32. PubMed ID: 18407718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes.
    Viswanathan V; Mohan V; Subramani P; Parthasarathy N; Subramaniyam G; Manoharan D; Sundaramoorthy C; Gnudi L; Karalliedde J; Viberti G
    Clin J Am Soc Nephrol; 2013 Feb; 8(2):225-32. PubMed ID: 23184569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
    Wolffenbuttel BH; Gomis R; Squatrito S; Jones NP; Patwardhan RN
    Diabet Med; 2000 Jan; 17(1):40-7. PubMed ID: 10691158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.
    Mudaliar S; Chang AR; Henry RR
    Endocr Pract; 2003; 9(5):406-16. PubMed ID: 14583425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
    Ratner RE; Cannon CP; Gerstein HC; Nesto RW; Serruys PW; Van Es GA; Kolatkar NS; Kravitz BG; Zalewski A; Fitzgerald PJ;
    Am Heart J; 2008 Dec; 156(6):1074-9. PubMed ID: 19033001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes.
    Buch HN; Baskar V; Barton DM; Kamalakannan D; Akarca C; Singh BM
    Diabet Med; 2002 Jul; 19(7):572-4. PubMed ID: 12099960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance.
    Varghese A; Yee MS; Chan CF; Crowe LA; Keenan NG; Johnston DG; Pennell DJ
    J Cardiovasc Magn Reson; 2009 Jul; 11(1):24. PubMed ID: 19635160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone improves exercise capacity in individuals with type 2 diabetes.
    Regensteiner JG; Bauer TA; Reusch JE
    Diabetes Care; 2005 Dec; 28(12):2877-83. PubMed ID: 16306548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial.
    Gerstein HC; Ratner RE; Cannon CP; Serruys PW; García-García HM; van Es GA; Kolatkar NS; Kravitz BG; Miller DM; Huang C; Fitzgerald PJ; Nesto RW;
    Circulation; 2010 Mar; 121(10):1176-87. PubMed ID: 20194881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.
    Tan KCB; Chow WS; Tso AWK; Xu A; Tse HF; Hoo RLC; Betteridge DJ; Lam KSL
    Diabetologia; 2007 Sep; 50(9):1819-1825. PubMed ID: 17639302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes.
    Smith SA; Porter LE; Biswas N; Freed MI
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6048-53. PubMed ID: 15579757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinedione-induced edema in patients with heart failure.
    Stroup JS
    Am J Health Syst Pharm; 2007 Dec; 64(23):2426-30; author reply 2430. PubMed ID: 18029947
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy.
    Pistrosch F; Passauer J; Herbrig K; Schwanebeck U; Gross P; Bornstein SR
    Horm Metab Res; 2012 Nov; 44(12):914-8. PubMed ID: 22723267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
    ; Gerstein HC; Yusuf S; Bosch J; Pogue J; Sheridan P; Dinccag N; Hanefeld M; Hoogwerf B; Laakso M; Mohan V; Shaw J; Zinman B; Holman RR
    Lancet; 2006 Sep; 368(9541):1096-105. PubMed ID: 16997664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.